(Reuters) -Zimmer Biomet Holdings cut its 2025 organic revenue growth forecast following weakness in Latin America and emerging markets in Europe that offset the company’s strong performance in the U.S., sending shares 8.4% lower in premarket trading.

The medical device maker kept its overall revenue growth forecast stable on Wednesday, aided by foreign currency fluctuations. But it lowered the upper end of its organic growth outlook to 4.0% from 4.5%, while keeping the floor constant at 3.5%.

Zimmer said these issues emerged late in the quarter and are being addressed.

For the quarter, the company saw strong demand for its hips and knees units, which help with joint reconstruction procedures, underpinned by sustained demand for surgical procedures, especially among older adults.

J.P.M

See Full Page